Announcement PDF Emyria ASX Announcement | 20 April 2026 ASX RELEASE. 20 April 2026 EMYRIA LAUNCHES GLOBAL SERVICES PLATFORM TARGETING INTERNATIONAL DRUG SPONSORS Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors. Key Highlights: • Emyria establishes dual-revenue model with launch of global services platform - Introduces high-margin, sponsor-funded revenue opportunity alongside existing reimbursed treatment programs, marking a strategic global inflection point. • Already operational with North American based sponsor Psyence Group (CSE: PSYG and OTCQB: PSYGF) - Demonstrates immediate commercial application and validates Emyria as a trusted clinical delivery partner. • US Government moves to fast-track next-generation mental health treatments – The US confirms Executive Order for policy action to accelerate research into psychedelic drugs with a view to expediting medical treatments for serious mental illness1 . • Solving a critical global bottleneck in therapy rollout - Clinical delivery capacity, not drug development, is emerging as a key constraint in next-generation mental health treatments. • Scarce clinical infrastructure built over multiple years - Emyria’s national network, trained workforce and governance capability are difficult and time-intensive to replicate. • High-margin, capital-light services model supported by strong inbound demand - Growing engagement from global CROs and drug sponsors expected to drive revenue opportunity and scalable expansion. Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery infrastructure. The launch represents a strategic inflection point, positioning Emyria as a global clinical delivery platform, and establishes a dual-revenue model combining existing reimbursed treatment programs with high-margin, sponsor-funded services. The Program provides a structured pathway for drug sponsors and clinical research organisations (CROs) to deliver complex treatment protocols through Emyria’s Empax network, supporting both clinical trial execution and post-approval commercial rollout. ASX RELEASE Emyria ASX Announcement | 20 April 2026 2 Global Inflexion Point Driving Immediate Demand More than 50 psychedelic-assisted therapy programs are currently in global clinical development2 , targeting large and under-served patient populations across PTSD, treatment- resistant depression and other serious mental health conditions. Unlike traditional pharmaceuticals, these therapies require: • Intensive psychotherapy • Long-duration treatment sessions • Purpose-built clinical environments • Highly trained, multidisciplinary teams As a result, clinical delivery capacity—not drug development—is emerging as a primary constraint to global rollout. This dynamic is being reinforced by accelerating government and regulatory momentum, particularly in the United States where recently announced Executive Order to enact policy initiatives are focused on accelerating research on psychedelic drugs with a view to expediting medical treatments for serious mental illness1 . A Scarce and Differentiated Clinical Delivery Platform Emyria has spent several years building the infrastructure, workforce and clinical governance required to safely deliver complex mental health therapies at scale. Through its Empax network, the Company offers: • Established treatment programs across PTSD and treatment-resistant depression (TRD) • National patient access pathways supported by strong referral demand • A trained workforce of ~100 therapists and specialist psychiatrists • Purpose-built clinical environments, including private hospital infrastructure • Advanced clinical governance, including TGA engagement, licensing, ethics approvals, drug logistics and protocol design In addition, Emyria captures standardised, longitudinal real-world outcome data, with published results demonstrating durable remission outcomes in treatment-resistant PTSD at 12 months and beyond3 . This combination of infrastructure, workforce, governance and data represents a highly differentiated and difficult-to-replicate clinical delivery platform. High-Margin Services Model with Immediate Application Under the Empax Global Partnership Program, international drug sponsors engage Emyria to plan and execute clinical delivery, leveraging already-operational infrastructure, clinicians and governance systems. This enables: • Rapid deployment of complex clinical protocols • Reduced execution risk for sponsors • Efficient scaling from clinical trials through to commercial rollout Sponsor-funded clinical delivery is expected to command premium commercial rates, reflecting the complexity and scarcity of the required expertise and infrastructure. ASX RELEASE Emyria ASX Announcement | 20 April 2026 3 Importantly, the model is capital-light and leverages Emyria’s existing platform, supporting high-margin, incremental revenue generation alongside reimbursed treatment programs. The Company is already receiving positive inbound interest from global CROs and sponsors. Fees generated from the service will typically be on normal commercial terms based on the agreed services. Already operational, additive to the core business Emyria is currently supporting delivery work for international drug sponsor Psyence Group, through being a clinical trials site for a Phase IIb trial in Adjustment Disorder in patients with advanced cancer, demonstrating that its Empax platform is already operational, compliant and trusted by international developers. The Empax Global Partnership Program formalises this offering for the broader Sponsor community, and is expected to generate additive services revenue without diverting focus from Emyria’s growing patient capacity across Perth,4,5 Brisbane6 and the Mornington Peninsula,7 with NSW recruitment underway.8 Table 1 – Psychedelic Drug Development Bullseye Chart, Segmented by Molecule Group9 Executive Chair Greg Hutchinson commented: “The experience and infrastructure required to safely deliver these therapies in complex patient populations is scarce and highly valuable. Emyria has spent years building this capability. The Empax Global Partnership Program makes that capability available to international drug sponsors developing the next generation of mental health treatments. We are already delivering for Psyence Group and are seeing positive inbound interest from sponsors and CROs seeking scalable, compliant clinical delivery solutions. Psyence Group ASX RELEASE Emyria ASX Announcement | 20 April 2026 4 Our ambition is to play a leading global role in enabling these therapies to reach patients at scale, while generating high-margin, capital-light revenue for the Company.” This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson | Executive Chair 1300 436 363 | investors@emyria.com References: 1. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical- treatments-for-serious-mental-illness/ 2. Psychedelic Alpha, Psychedelic Drug Development Tracker: https://psychedelicalpha.com/resources/psychedelic-drug- development-tracker/ 3. See ASX release 02 Feb 2026 4. See ASX release 18 June 2025 5. See ASX release 14 April 2025 6. See ASX release 13 August 2025 7. See ASX release 29 Jan 2026 8. See ASX release 02 April 2026 9. https://psychedelicalpha.com/news/q1-2026-psychedelic-drug-development-pipeline-bullseye-charts/ Emyria ASX Announcement | 20 April 2026 ASX RELEASE. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs